TY  - JOUR
AU  - Sun, Qiang
AU  - Melino, Gerry
AU  - Amelio, Ivano
AU  - Jiang, Jingting
AU  - Wang, Ying
AU  - Shi, Yufang
TI  - Recent advances in cancer immunotherapy.
JO  - Discover oncology
VL  - 12
IS  - 1
SN  - 1868-8497
CY  - [New York]
PB  - Springer
M1  - DZNE-2022-00084
SP  - 27
PY  - 2021
N1  - Journal: Discover Oncology, ISSN: 2730-6011
AB  - Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.
KW  - Cancer immunotherapy (Other)
KW  - Cancer survival (Other)
KW  - Immune check point blockade (Other)
KW  - KRas (Other)
KW  - T cell receptor (Other)
KW  - p53 (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:35201440
C2  - pmc:PMC8777500
DO  - DOI:10.1007/s12672-021-00422-9
UR  - https://pub.dzne.de/record/163304
ER  -